Abstract
A series of C3 halobenzyl-substituted tricyclic HIV integrase inhibitors was prepared. Improvement in cell-based inhibitor potency was observed in comparison to previously disclosed tricyclic pyrroloquinolines carrying the 'halobenzyl tail' at the lactam nitrogen. Animal PK for several of the C3-substituted inhibitors was examined, with a dihaloaryl analog achieving good balance in protein-shifted EC(50) and t(1/2) in animal PK studies.
MeSH terms
-
Administration, Oral
-
Animals
-
Anti-HIV Agents / chemical synthesis*
-
Anti-HIV Agents / chemistry
-
Anti-HIV Agents / pharmacology*
-
Dogs
-
Drug Design
-
HIV Integrase Inhibitors / chemical synthesis*
-
HIV Integrase Inhibitors / chemistry
-
HIV Integrase Inhibitors / pharmacology*
-
Humans
-
Molecular Structure
-
Pyrroles / chemical synthesis*
-
Pyrroles / chemistry
-
Pyrroles / pharmacology*
-
Quinolines / chemical synthesis*
-
Quinolines / chemistry
-
Quinolines / pharmacology*
-
Rats
-
Structure-Activity Relationship
Substances
-
Anti-HIV Agents
-
HIV Integrase Inhibitors
-
Pyrroles
-
Quinolines
-
pyrroloquinoline